CIK 0000310158
- Large accelerated filer
Merck & Co., Inc.
Sign in to watch- Ticker
- MRK
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NJ
- Entity type
- Operating
- EIN
- 221918501
- Phone
- +1 908-740-4000
- Business address
- 126 EAST LINCOLN AVENUE, P.O. BOX 2000, RAHWAY, NJ, 07065
- Former names
- Merck & Co. Inc., SCHERING PLOUGH CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $8,611,875
- in 1 filing
Net −$8,611,875. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-24 | Klobuchar Michael A EVP - Chief Strategy Officer | Grant or award | +2,994 | $73.51 | $220K | 14,058.93 |
| 2022-02-24 | Karachun Rita A Sr. VP Fince-Global Controller | Grant or award | +3,478 | $73.51 | $256K | 39,276.97 |
| 2022-02-24 | Gerberding Julie L. EVP, Chief Patient Officer | Grant or award | +9,550 | $73.51 | $702K | 48,712.14 |
| 2022-02-24 | FRAZIER KENNETH C Executive Chair | Grant or award | +119,488 | $73.51 | $8.8M | 706,283.06 |
| 2022-02-24 | DeLuca Richard R. EVP&Pres, Merck Animal Heallth | Grant or award | +15,966 | $73.51 | $1.2M | 133,896.54 |
| 2022-02-24 | Chattopadhyay Sanat Exe V-P & Pres. MMD | Grant or award | +19,836 | $73.51 | $1.5M | 112,981.36 |
| 2022-02-24 | Davis Robert M CEO & President | Grant or award | +29,896 | $73.51 | $2.2M | 247,592.76 |
| 2022-02-10 | Williams David Michael EVP,Chief Info&Digital Officer | Option exercise | +1,202 | $76.53 | $92K | 7,420.76 |
| 2022-02-10 | Williams David Michael EVP,Chief Info&Digital Officer | Shares withheld for taxes | −477 | $76.53 | $37K | 6,943.76 |
| 2022-02-10 | Williams David Michael EVP,Chief Info&Digital Officer | Option exercise · Restricted Stock Unit | −1,202 | 1,205 | ||
| 2021-12-31 | Coe Mary Ellen Director | Grant or award · Phantom Stock | +424.06 | $76.64 | $32K | 12,841.99 |
| 2021-12-31 | GLOCER THOMAS H Director | Grant or award · Phantom Stock | +146.79 | $76.64 | $11K | 79,894.3 |
| 2021-12-31 | Seidman Christine E Director | Grant or award · Phantom Stock | +212.03 | $76.64 | $16K | 7,105 |
| 2021-12-31 | WENDELL PETER C Director | Grant or award · Phantom Stock | +391.44 | $76.64 | $30K | 110,151.91 |
| 2021-11-09 | FRAZIER KENNETH C Executive Chair | Option exercise | +663,881 | 1,250,676.06 | ||
| 2021-11-09 | FRAZIER KENNETH C Executive Chair | Sale | −634,266 | $82.22 | $52.1M | 616,410.06 |
| 2021-11-09 | FRAZIER KENNETH C Executive Chair | Sale | −29,615 | $83.23 | $2.5M | 586,795.06 |
| 2021-11-09 | FRAZIER KENNETH C Executive Chair | Option exercise · Stock Option (Right to Buy) | −663,881 | 0 | ||
| 2021-11-04 | DeLuca Richard R. EVP&Pres, Merck Animal Heallth | Option exercise | +29,782 | 146,711.96 | ||
| 2021-11-04 | DeLuca Richard R. EVP&Pres, Merck Animal Heallth | Sale | −29,782 | $90.40 | $2.7M | 116,929.96 |
Page 39 of 42 · 823 trades